Skip to content
Syenza News
  • Home
  • Topics
    • Artificial intelligence and machine learning
    • Cost-Effectiveness Analysis
    • Infectious diseases
    • Health Equity and Access to Care
    • HTA
    • Oncology Research
  • Region
    • Europe
    • North America
    • Sub-Saharan Africa
  • Events
  • About
  • Visit Syenza
BACK TO MAIN SITE

First At-Home HPV Testing Approval: FDA Clears ...

By Rene Pretorius

May 13, 2025

Introduction The
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control
FDA AI Drug Approval
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis ...
Trodelvy Keytruda Combination Delivers Breakthrough Results in Metastatic Tri...
AI Pediatric Sarcoma Diagnosis: Improving Speed and Accuracy in Cancer Classi...
Urgent Need for Pediatric Heart Devices
Journavx for Pain Management: Toward Affordability and Access
FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough i...
Advancing Pediatric Leukemia Trial: Precision Medicine and Transformative Res...
« Previous 1 … 20 21 22 23 24 … 58 Next »

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

[email protected]

JOIN NEWSLETTER

This is required.
This is required.
This is required.

SERVICES

  • HEOR
  • Global Market Access
  • Dynamic Intelligence
  • Glossary of Terms
  • Advanced Degrees

QUICK LINKS

  • About
  • Case Studies
  • Insights
  • Art of Science
  • Careers
  • Contact Us
  • Copyright Notice
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
schedule a meeting
LINKEDIN
TWITTER

Disclaimer: Syenza News is an educational and informational platform. Content does not constitute clinical, medical, or professional healthcare advice.

© 2026 Syenza™. All rights reserved.

Made with heart by Frogiez

schedule a meeting
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}